Avience Biomedicals Limited (NSE:AVIENCE)
India · Delayed Price · Currency is INR 346.80
+10.45 (3.11%)
At close: Sep 10, 2026
Avience Biomedicals Revenue
In the fiscal year ending March 31, 2026, Avience Biomedicals had annual revenue of 525.06M INR with 16.07% growth. Avience Biomedicals had revenue of 122.35M in the quarter ending March 31, 2025.
Revenue
525.06M
Revenue Growth
+16.07%
P/S Ratio
3.62
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 525.06M | 72.70M | 16.07% |
| Mar 31, 2025 | 452.36M | 212.72M | 88.77% |
| Mar 31, 2024 | 239.64M | 130.38M | 119.32% |
| Mar 31, 2023 | 109.26M | 7.79M | 7.68% |
| Mar 31, 2022 | 101.48M | 90.14M | 795.59% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jay Jalaram Technologies | 8.52B |
| Shreyans Industries | 6.29B |
| Integrated Personnel Services | 4.01B |
| Sat Kartar Life | 2.01B |
| Eppeltone Engineers | 1.35B |
| Rockingdeals Circular Economy | 1.20B |
| Neochem Bio Solutions | 1.11B |
| Pil Italica Lifestyle | 1.01B |